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Key Points: 36 
 37 
1. IL-15 has been implicated in central nervous system disease and 38 
leukaemogenesis but the biological mechanisms are unknown.  39 
2. IL-15 increases pre-B ALL growth and up-regulates CNS homing 40 
molecules. MEK/ERK, PI3K and NFκB inhibitors block IL-15 growth 41 
effects.  42 
 43 
ABSTRACT   44 
Genome-wide association studies and transcriptomics have consistently 45 
implicated the interleukin-15 (IL-15) gene in acute lymphoblastic leukaemia 46 
(ALL) biology, including associations with disease susceptibility, resistance to 47 
initial therapy and increased risk of mediastinal and central nervous system 48 
(CNS) involvement. However, whether pre-B ALL blasts directly respond to IL-49 
15 is currently unknown. Here we show that the majority of pre-B ALL primary 50 
samples and cell lines express IL-15 and all 3 components of its 51 
heterotrimeric receptor and that primary pre-B ALL cells show increased 52 
growth in culture in response to IL-15. Investigation of mechanisms of action 53 
using highly IL-15 responsive SD-1 cells shows this growth advantage is 54 
maximal under low serum conditions, mimicking those found in cerebrospinal 55 
fluid. Addition of IL-15 also up-regulates PSGL-1 and CXCR3, molecules 56 
associated with lymph-node and CNS trafficking. Investigation of downstream 57 
signalling pathways indicates that IL-15 induces STAT5, ERK1/2 and to a 58 
lesser extent PI3K and NFκB phosphorylation. The IL-15 mediated growth 59 
advantage is abolished by MEK/ERK, PI3K and NFκB inhibitors, but 60 
preserved in the presence of STAT5 inhibition. Together these observations 61 
provide a plausible mechanistic link between increased levels of IL-15 62 
expression and leukaemogenesis, high-risk disease, mediastinal involvement 63 
and CNS relapse and suggest potential therapeutic targets. 64 
 65 
 66 
 67 
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INTRODUCTION 68 
 69 
Large-scale unbiased genomic approaches are increasingly used in 70 
leukaemia research to identify factors that influence tumourigenesis, biological 71 
features and/or response to therapy. Genetic “hits” identified by these 72 
investigations may be directly involved in the disease or bystanders 73 
incidentally-linked to other (often unknown) genetic loci that drive the process. 74 
For this reason it is important to verify the biological role of implicated genes if 75 
progress is to be made. Several large observational studies have linked 76 
interleukin-15 (IL-15) single-nucleotide polymorphisms (SNPs) or mRNA 77 
levels to aspects of acute lymphoblastic leukaemia (ALL) biology. Two 78 
independent genome-wide association studies (GWAS) identified 79 
polymorphisms in the IL-15 gene as predictors of leukaemia development1 80 
and resistance to initial therapy2. Microarray data suggest that IL-15 mRNA 81 
levels predict the likelihood of central nervous system (CNS) relapse in 82 
childhood ALL3. Finally, a clinical study looking at IL-15 mRNA in adult ALL 83 
showed that higher IL-15 expression was associated with mediastinal and 84 
lymph node (LN) infiltration but not hepatosplenomegaly (rates of CNS 85 
involvement were not reported)4. Importantly some IL-15 SNPs correlate with 86 
increased promoter activity when tested in reporter constructs5, suggesting a 87 
possible direct link to pathogenesis. However, the mechanisms underlying any 88 
biological advantage for high IL-15 expression in ALL are currently unknown. 89 
 90 
IL-15 is a pleiotropic cytokine sharing structural homology and receptor 91 
components with interleukin-2 (IL-2)6,7; together these cytokines play pivotal 92 
roles in regulatory and effector functions of the normal immune system. IL-15 93 
influences proliferation, differentiation, resistance to apoptosis8 and cellular 94 
localization of T9 and B lymphocytes10, neutrophils11 and natural killer (NK) 95 
cells12. A possible role for IL-15 in malignant disorders of the immune system 96 
was first suggested by its identification in an Adult T-cell Leukaemia-97 
Lymphoma (ATLL) cell line13 and the fact that IL-15 transgenic mice develop 98 
an NK/T large granular lymphocyte leukaemia (LGL) like disease14,15. IL-15 99 
stimulates proliferation of primary T-ALL blasts in culture16 and chronic 100 
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exposure of normal LGLs to IL-15 induces leukaemic transformation17. Links 101 
to B-cell malignancies – myeloma18 and CLL19,20 have also been reported.  102 
 103 
The IL-15 gene is expressed in many tissues including the central nervous 104 
system21,22. Two IL-15 isoforms encode the same mature IL-15 protein but 105 
with different signal peptides determining cellular localisation23. The 21 amino-106 
acid short-signal peptide isoform (SSP-IL-15) is targeted to the cytoplasm – its 107 
function remains largely unknown. In contrast, the 48 amino-acid long-signal 108 
peptide isoform (LSP-IL-15) targets IL-15 for presentation on the cell-surface 109 
and/or secretion. IL-15 signals via a heterotrimeric receptor complex 110 
comprising a common γ chain, an IL-2/IL-15Rβ chain6 and a specific IL-15Rα 111 
chain24. This IL-15Rα chain binds IL-15 with high-affinity (1000 fold higher 112 
than IL-2/IL-2Rα interactions24) and can be secreted or membrane bound. IL-113 
15/IL-15Rα heterodimers may be the main active form of IL-15 in human 114 
serum25. Thus, IL-15 can be presented in cis or trans and act in an autocrine, 115 
paracrine or juxtacrine fashion. It is unknown whether the reported 116 
associations between IL-15 SNPs and ALL reflect a direct biological role for 117 
IL-15 in ALL. If so, this could be due to direct effects of IL-15 on leukaemic 118 
blasts or indirect effects via IL-15 modulation of the immune system or a 119 
combination of the two.  120 
 121 
In this study we investigate the biological effect of IL-15 in pre-B ALL. We 122 
show that IL-15 is expressed by pre-B ALL blasts, which respond to both 123 
autocrine and paracrine IL-15 signalling. We show that the growth advantage 124 
of leukaemic blasts exposed to IL-15 is maximal under low-serum conditions 125 
and identify downstream pathways responsible for the growth advantage. 126 
Thus, we have identified possible therapeutic targets that could be used to 127 
treat high-risk disease and/or CNS relapse.  128 
129 
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MATERIALS AND METHODS 130 
 131 
Cell culture and primary cells 132 
Human ALL cell lines SD-1, REH, Molt-4, Sup-B15, SEM and CCRF-CEM 133 
were maintained in RPMI supplemented with 10% FBS and 1% 134 
Penicillin/Streptomycin (Invitrogen). Pre-B ALL primary samples were 135 
obtained from the Leukaemia Lymphoma Research Childhood Leukaemia 136 
Cellbank and from our local institutions. Cells used for receptor expression 137 
analysis were cultured in complete RPMI, at 37oC, 5% CO2 for 24h before 138 
harvesting in Trizol (Invitrogen). Primary cells were processed and 139 
cryopreserved as previously described26. For growth curves, primary cells 140 
were thawed and set up in suspension culture in HP01 media (Macopharma) 141 
supplemented with rhIL-3 (20ng/ml), rhIL-7 (20ng/ml) and rhSCF(50ng/ml) (3-142 
cytokine mix) (all R&D systems)27. After 7-14 days in culture (recovery time) 143 
these cells were washed and split in to two conditions: 3-cytokine mix only or 144 
3-cytokine mix + rhIL-15 (25ng/ml) (Peprotech).  Cells were maintained over a 145 
3-week period with weekly half-media changes. Viability and absolute cell 146 
counts (live lymphoid blasts) were determined using a MACSQuant flow 147 
cytometer (Miltenyi Biotec) after staining with 7-Aminoactinomycin-D 148 
(Invitrogen).  Patient’s details are given in supplementary table 1. This project 149 
was approved by the West of Scotland Research Ethics Committee. 150 
 151 
Xenotransplants 152 
NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) breeders were obtained from Charles 153 
River, Europe and the colony maintained at the Central Research Facility, 154 
University of Glasgow. Mice were kept in sterile isolators with autoclaved food, 155 
bedding and water. At 6-8 weeks of age mice were injected intravenously with 156 
1x106 leukaemic cells via tail vein. Mice were sacrificed at 6 weeks post-157 
injection or earlier if unwell. All animal experiments were approved by the 158 
University of Glasgow Ethical Review Process Committee.   159 
 160 
Histology 161 
Murine brains were fixed in 10% neutral-buffered formalin and paraffin 162 
embedded. Haematoxylin and Eosin staining (Sigma) was performed on 5µm 163 
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brain sections. Anti-CD45 immunohistochemistry used standard protocols; 164 
paraffin-embedded sections were dewaxed and hydrated prior to antigen 165 
retrieval at 1000C for 15 minutes in 0.01 mol/L citrate buffer, pH 6.0. Following 166 
blocking in 20% horse serum/PBS-Tween20 (0.05%) (PBST) with avidin 167 
block, sections were incubated with mouse anti-human CD45 antibody/isotype 168 
control antibody (mouse IgG1) (Dako) and horse, biotinylated anti-mouse – 169 
secondary antibody (Vector Laboratories) with biotin block. Sections were 170 
treated with ABC kit (Vector Laboratories) and DAB to visualise antibody 171 
binding. All imaging was performed on an Axiostar plus microscope and 172 
images were acquired using Axiovision Rel 4.2 software (Carl Zeiss, 173 
Oberkochen Germany) 174 
 175 
PCR 176 
Total RNA was extracted using an RNeasy kit (Qiagen) or following 177 
homogenization in Trizol. All samples underwent DNase digestion (RNase-178 
free DNase, Qiagen). RNA (200ng) was reverse-transcribed using random 179 
primers and AffinityScript reverse transcriptase (Stratagene). RT-PCR used 180 
standard cycling conditions on an Applied Biosystems Veriti thermal cycler. 181 
Primary cell IL-15 qPCR was performed using PerfeCTa SYBR Green 182 
FastMix, ROX (Quanta Biosciences). Primers were designed using Primer3 183 
software. IL-15R quantitative PCR used Taqman primers and probes with 184 
Universal Mastermix (Applied Biosystems). Custom designed Taqman low 185 
density arrays (TLDA) were run as previously described28. Data were 186 
analysed using RQ Manager 1.2.4 software (Applied Biosystems). The RT2 187 
Human tumour metastasis profiler arrays (Catalogue number PAHS-028ZC-2) 188 
(SABiosciences) were run using SYBR green ROX qPCR Mastermix 189 
(SABiosciences) according to the manufacturer’s instructions. All qPCR 190 
reactions were performed using the Applied Biosystems 7500/7900HT Real-191 
PCR System. PCR primer details and assay IDs are listed in supplementary 192 
table 2. 193 
 194 
Flow cytometry and Annexin V assays 195 
CXCR3 and PSGL-1 antibodies were obtained from Ebioscience. Intracellular 196 
IL-15 was detected using anti-human IL-15-PE antibodies/isotype control 197 
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(R&D systems) following fixation and permeabilization using BD 198 
Cytofix/Cytoperm (BD Biosciences) according to the manufacturer’s 199 
instructions. Apoptosis was determined via the Annexin V apoptosis detection 200 
kit FITC (Ebioscience) according to the manufacturer’s instructions. Data were 201 
acquired on a MACSQuant flow cytometer (Miltenyi Biotec) and results were 202 
analysed using FlowJo7.2.4 software (Tree Star Inc, OR, USA). 203 
 204 
Western blotting  205 
Cells were lysed in RIPA buffer (Sigma) with protease/phosphatase cocktail 206 
inhibitor (1:100 dilution – Sigma). 10 g total protein (determined using a BCA 207 
protein assay kit, Thermoscientific) was run on a 12% bis-tris gel (Invitrogen) 208 
and transferred via iBlot (Invitrogen) to nitrocellulose membrane. Blocking was 209 
performed in 10% non-fat milk (0.05% Tween/PBS). All antibodies were 210 
purchased from New England Biolabs and used at 1:1000 dilutions unless 211 
otherwise stated. Chemiluminescence was detected using West Femto super 212 
signal (Thermoscientific).  213 
 214 
SD-1 Growth curves and inhibitors 215 
SD-1 and Sup-B15 cells were seeded into 24 well flat bottom plates at 1.5 x 216 
105 cells/ml. Viable cells were counted using a haemocytometer with trypan-217 
blue dead-cell exclusion. Cells were exposed to IL-15R neutralizing antibody 218 
(nAb) (R & D Systems), isotype control antibody (R & D Systems), or rhIL-15. 219 
Small molecule inhibitors of signalling pathways were diluted in DMSO and 220 
added to cells with or without addition of 25ng/ml IL-15 and growth was 221 
compared to cells grown in the same percentage of DMSO (vehicle controls). 222 
Cell division was assessed using the CellTrace Violet proliferation kit 223 
(Invitrogen) using colcemid treated cells as a non-dividing control29. 224 
 225 
MTT assays 226 
120 µl of MTT (5 mg/ml) (Sigma) in PBS was added to each well of 24-well 227 
plates containing SD-1 cells and incubated for 4 h at 37 °C. Following 228 
centrifugation and removal of supernatant, 600 µl of extraction reagent (Fisher 229 
Scientific) was added per well and agitated for 15mins. 100 µl solution/well 230 
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was then transferred to a 96-well plate and absorbance measured in a sunrise 231 
absorbance reader (Tecan) at 570 nm (background wavelength 660 nm). 232 
Analysis used MagellanCE6 software (Tecan).  233 
 234 
Statistics 235 
Parametric data were analysed using Student’s unpaired t-tests. Non-236 
parametric data were analysed using Mann-Whitney (2 groups, unpaired), 237 
Kruskal-Wallis (>2 groups, unpaired) or Wilcoxon matched-pairs sign rank (>2 238 
groups, paired) tests. A p-value of ≤0.05 was considered significant. All 239 
analysis was carried out using GraphPad Prism software (La Jolla, CA). 240 
 241 
RESULTS 242 
 243 
Leukaemic blasts express IL-15 and IL-15 receptors and levels correlate with 244 
CNS infiltration in xenografts.  245 
RT-PCR was used to investigate expression of the two IL-15 isoforms and 246 
three IL-15 receptor subunits in pre-B ALL cell lines; SD-1, Sup-B15, REH and 247 
SEM, and 19 primary pre-B leukaemic diagnostic samples (patient and cell 248 
line details; Supplementary Table 1). All expressed the cell-surface/secreted 249 
LSP-IL-15 isoform, but expression of the cytoplasmic SSP-IL-15 isoform was 250 
only detected in 6/19 primary samples (Figure 1a and Supplementary Table I). 251 
In addition, all samples expressed IL-15Rα and the common γ chain and 252 
14/17 primary samples expressed IL-15Rβ (Figure 1a). This suggests that the 253 
majority of ALL cells have the potential to secrete and respond to IL-15 using 254 
autocrine, juxtacrine or paracrine signalling loops.  255 
 256 
Quantitative PCR indicates that primary ALL samples show a spectrum of IL-257 
15 mRNA expression (Figure 1b). High expression has been shown to predict 258 
cytospin positive CNS disease at diagnosis and the risk of CNS relapse3. To 259 
examine the link with CNS disease further we used a xenograft model to 260 
investigate CNS infiltration by pre-B cell lines. All cell lines tested were 261 
capable of CNS infiltration (Figure 1c) but with different kinetics as measured 262 
by time to hind-limb paralysis (HLP), a surrogate marker for leukaemic 263 
infiltration of the leptomeninges (Figure 1d). Higher expression levels of 264 
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mRNA encoding IL-15 and all 3 components of the IL-15 receptor (Figure 1e-265 
h) were associated with shorter time to HLP (Figure 1d).  266 
 267 
Pre-B ALL cells can respond directly to IL-15 268 
To test whether IL-15 mediates direct effects on pre-B ALL cells, 6 primary 269 
samples (patient details in supplementary table 1) and 4 pre-B ALL cell lines 270 
(SD-1, Sup-B15, REH and SEM) were exposed to IL-15 in suspension culture 271 
and the effects on growth were examined. Five of six primary samples (Figure 272 
2a) showed increased cell numbers in the presence of IL-15. To account for 273 
the wide variation in starting cell numbers and differing rates of proliferation 274 
between primary samples we also calculated fold change in cell numbers 275 
compared to baseline (Figure 2b) – this confirmed that IL-15 significantly 276 
enhanced cell growth when added to standard 3-cytokine mix. The effect of 277 
IL-15 on cell lines is more restricted and is shown in Figure 2c, SD-1 cells 278 
show a dose-dependent response to exogenous IL-15 but other cell lines 279 
appear to be IL-15 independent. To investigate whether endogenous IL-15 280 
also plays a role, cells were incubated with an IL-15R nAb (in the absence of 281 
an exogenous source of IL-15) to block autocrine IL-15 signalling but leave 282 
signalling from IL-2 (which uses the same beta/gamma receptor subunit) and 283 
other cytokines (that use the common gamma chain) unaffected. Exposure of 284 
to IL-15R nAbs significantly decreased cell number at both 72 and 96 h in 285 
SD-1 but not Sup-B15 cells (Figure 2d).  286 
These experiments show that pre-B ALL samples can respond directly to 287 
addition of IL-15 in culture resulting in increased growth. 288 
 289 
Mechanism of action of IL-15 in promoting pre-B ALL growth.  290 
To investigate the mechanism of IL-15 action on pre-B ALL blasts, Sup-B15 291 
and SD-1 cells were studied further, since they carry the same leukaemic 292 
translocation – t(9;22) BCR-ABL - but differ markedly in their IL-15 expression 293 
levels and speed of onset of CNS disease; high in SD-1 cells and low in Sup-294 
B15 cells (Figure 1d).  295 
 296 
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IL-15 protein is difficult to detect due to its highly controlled secretion and fast 297 
turnover25,30. Consistent with previous reports18 IL-15 secretion was 298 
undetectable using ELISA (sensitivity ≥8pg/ml, data not shown). However, 299 
intracellular IL-15 protein was detectable by flow cytometry in SD-1 cells, with 300 
lower levels in Sup-B15 (Figure 3a). Western blotting confirmed all three IL-15 301 
receptor components are expressed by both cell lines with higher levels of IL-302 
15Rα in SD-1 than Sup-B15 (Figure 3b). 303 
 304 
The observed increased cell numbers in the presence of IL-15 (Figure 2) 305 
could reflect reduced apoptosis or an ability to withstand growth arrest under 306 
conditions of serum depletion. IL-15 has powerful anti-apoptotic effects in T 307 
and B cells8,31. Therefore we investigated whether IL-15 affected apoptosis in 308 
SD-1 cells. There was no alteration in BCL-xL and BCL-2 levels (Figure 3c) 309 
and no differences in apoptosis between IL-15 and untreated SD-1 cells 310 
measured by PARP cleavage (Figure 3d), Annexin V staining (Figure 3e) or 311 
caspase-3 cleavage (supplementary figure 1a).  To uncover a potential anti-312 
apoptotic role for IL-15 in the context of induced apoptotic stress, SD-1 cells 313 
were treated with dexamethasone (100 nM, 1 M and 10 M) for 48 hours to 314 
induce apoptosis. Dexamethasone had no effect on SD-1 apoptosis or 315 
viability, assessed using Annexin V (Figure 3f) and MTT (Figure 3g) 316 
respectively. Importantly, this could not be overcome by treatment with IL-317 
15R nAb (Figure 3h) suggesting that IL-15-IL-15Rsignalling is not 318 
responsible for the resistance of SD-1 cells to dexamethasone-induced 319 
apoptosis.  320 
 321 
Together these findings argue against reduced apoptosis being responsible 322 
for the higher plateau in IL-15 treated SD-1 cells.  An alternative explanation is 323 
that IL-15 prevents growth arrest under conditions of serum depletion (as 324 
seen after 72-96 hours in culture without replenishment of growth media). To 325 
test this, SD-1 and Sup-B15 cells were grown under no/low serum conditions 326 
with or without IL-15. IL-15 significantly enhanced the proliferation of SD-1 327 
cells growing under conditions of no serum, 1% and 2.5% serum (Figure 4a, b 328 
and supplementary Figure 1). Maximal benefit (in terms of percentage 329 
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increase in growth with IL-15 treatment) was seen with 0% and 1% serum 330 
conditions (figure 4b and c). Sup-B15 cells showed no response (Figure 4c). 331 
Again there was no evidence that the IL-15 growth advantage was due to 332 
rescue from apoptosis (Figure 4d and supplementary figure 1).  333 
 334 
Thus, IL-15R neutralisation reduces, and exogenous IL-15 stimulates, 335 
proliferation of SD-1 cells. These effects are not mediated via alterations in 336 
apoptosis. The significant growth advantage conferred by IL-15 treatment 337 
under low serum conditions provides a potential explanation for the 338 
association between high IL-15 expression and leukaemia relapse in the low-339 
protein environment of the CNS.  340 
 341 
IL-15 is not directly chemotactic but up-regulates PSGL1, CXCR3 and 342 
SERPINE1.  343 
In addition to its growth effects, IL-15 could play a role in leukocyte trafficking 344 
either acting as a chemoattractant32,33 or by modulating homing34,35. Since IL-345 
15 is expressed in the CNS21,22 we tested whether IL-15 affected chemotaxis 346 
of SD-1 cells but were unable to show any migration towards an IL-15 347 
gradient (Figure 5a). To investigate whether IL-15 indirectly regulates cellular 348 
migration or metastasis, two expression arrays were performed on IL-15 349 
treated SD-1 cells. Firstly, a Taqman low density array of 30 human 350 
chemokine receptors, integrins and selectins examined whether IL-15 351 
treatment up-regulated known leukocyte homing molecules. Only 2 out of 30 352 
genes showed significant up-regulation (Supplementary Figure 2): the 353 
chemokine receptor, CXCR3 and the selectin ligand, platelet selectin 354 
glycoprotein ligand-1 (PSGL-1/SELPLG). Interestingly, both are implicated in 355 
blood-CSF barrier transit36,37. These findings were confirmed by qPCR on an 356 
independent set of samples (Figure 5b) and up-regulation of PSGL-1 was also 357 
seen by flow cytometry (Figure 5c). We went on to show that leukaemic cells 358 
can migrate towards the CXCR3 ligand CXCL10 and that CXCL10 is 359 
detectable in CSF samples from patients with ALL. In addition, we show that 360 
the PSGL-1 receptor P-selectin is expressed on meningeal post-capillary 361 
venules in NSG mice (supplementary figure 3). 362 
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A second approach involved a RT2 PCR profiler array investigating 96 genes 363 
implicated in human tumour metastasis. IL-15 treatment had only a modest 364 
effect with just 7 genes showing greater than 2-fold up- or down-regulation 365 
(Figure 5d). Independent validation by qPCR confirmed that SERPINE1 was 366 
significantly, although modestly, up-regulated by IL-15 treatment (Figure 5e 367 
and supplementary figure 4).  368 
 369 
Together these experiments suggest that high IL-15 may increase interactions 370 
of circulating ALL cells with the blood-CSF and blood-LN barriers (via 371 
PSGL1/CXCR3) and/or promote invasiveness via SERPINE1 expression.  372 
 373 
IL-15 induces STAT5 and ERK1/2 phosphorylation  374 
Finally we investigated downstream signalling pathways that might mediate 375 
the effects of IL-15 in ALL using phospho-specific antibodies for ERK1/2, 376 
STAT5, IκBα and Akt. Strong phosphorylation of STAT5 and ERK1/2 was 377 
seen within 15 minutes of addition of IL-15 to SD-1 cells (Figure 6a-c). In 378 
addition, some activation of the NFκB and PI3K-Akt pathways is suggested by 379 
minor increases in phopsho-IκBα and phospho-Akt although these pathways 380 
are also constitutively activated in these cells (Figure 6a, 6d).  381 
 382 
Given the potential therapeutic benefit of blocking IL-15 signalling in ALL, 383 
small molecule inhibitors were investigated. Use of an ERK1/2 inhibitor 384 
(FR180204, Calbiochem) completely abolished the growth advantage 385 
conferred by IL-15 (Figure 7a). In contrast, STAT5 inhibition (573108, 386 
Calbiochem) reduced overall growth although the growth advantage of 387 
exogenous IL-15 was still maintained (Figure 7b and supplementary figure 5). 388 
A more potent MEK inhibitor (U0126, Calbiochem), which lies upstream of 389 
ERK1/2 in the Raf/Ras/ERK pathway, profoundly reduced the growth of SD-1 390 
cells and abolished any IL-15 stimulation of growth (Figure 7c and 391 
supplementary figure 5). Both PI3Kinase (LY 294002, Calbiochem) and NFκB 392 
(IKK-2 inhibitor IV, Calbiochem) inhibitors had profound effects on leukaemic 393 
cell growth both with and without IL-15 (figure 7d) making assessment of their 394 
specific role in IL-15 signalling difficult. 395 
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Together these results suggest that the Raf/Ras/ERK signalling pathway is 396 
directly involved in mediating IL-15 growth promoting effects whereas STAT5 397 
does not seem to play a role in this pathway. PI3K and NFκB may also be 398 
important either directly or indirectly in IL-15 action. 399 
 400 
DISCUSSION 401 
 402 
Here we have shown that IL-15 up-regulates leukocyte trafficking molecules 403 
and promotes cell proliferation under normal and hostile conditions in pre-B 404 
ALL. Thus we have established a mechanistic link between the effects of IL-405 
15 on leukaemic blasts and GWAS and microarray studies identifying IL-15 as 406 
a candidate gene for leukaemia development1, high-risk MRD2 and CNS 407 
relapse3. 408 
 409 
The GWAS data1,2 associate germline SNPs in IL-15 with leukaemia and 410 
therefore cannot distinguish the production of IL-15 by leukaemic blasts 411 
themselves or by the host microenvironment as the most important 412 
determinant of biological response. We show evidence for both; inhibition of 413 
autocrine or juxtacrine signalling via IL-15R neutralization reduced the 414 
growth of SD-1 cells, but larger growth-promoting effects were seen with 415 
exogenous IL-15, suggesting that paracrine signalling from the host 416 
microenvironment may be more important than autocrine signalling from the 417 
blasts themselves. All primary samples express IL-15 but a few samples lack 418 
expression of all components of the IL-15 receptor. This suggests that there 419 
may be heterogeneity between patients in the ability to respond to IL-15. 420 
Associations between IL-15 receptor expression and disease outcome have 421 
never been tested. Our sample size is too small to address this important 422 
question, but study of a larger cohort of patients could potentially identify 423 
patients that would benefit from blockade of IL-15 receptor signalling using 424 
pharmacological inhibitors as discussed below.  425 
 426 
High IL-15 expression in primary leukaemic blasts is correlated with CNS 427 
disease3. Leukaemic deposits in the CNS grow within the leptomeninges 428 
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bathed in CSF. CSF has a very low protein content38, a condition under which 429 
we show the growth enhancement effect of IL-15 is particularly marked. IL-15 430 
can promote survival in serum-free conditions in NK cells12 although in that 431 
case the effect was mediated via prevention of apoptosis rather than 432 
proliferation. We hypothesize that high levels of IL-15 facilitate engraftment 433 
and long term survival in the CNS. IL-15 may be more important in the CNS 434 
microenvironment than in the BM where serum-starvation is unlikely to be a 435 
major selective pressure. Importantly IL-15 is produced in the CNS by glial 436 
cells22 and high levels of IL-15 are associated with neuro-inflammatory 437 
disorders such as multiple sclerosis21, suggesting that IL-15 may be of 438 
particular importance in brain pathology.  439 
 440 
In addition to local effects on cell proliferation and survival, IL-15 may facilitate 441 
extramedullary dissemination of ALL, promoting bulky mediastinal and LN 442 
disease4 and CNS relapse3. IL-15 is directly chemotactic to T cells32,33 and NK 443 
cells39 and also indirectly influences leukocyte trafficking. IL-15R knockout 444 
mice have low numbers of circulating T and B cells and fewer leukocytes in 445 
lymph nodes, despite grossly normal B and T cell development35. IL-15 also 446 
plays a part in the regulation of immature B cell homing via modulation of 447 
IFNmediated homing pathways34. The induction of PSGL-1 by IL-15 may 448 
alter leukocyte trafficking; PSGL-1 is a ligand for both L and P selectins, the 449 
major determinants of tethering and rolling in LN endothelial venules40. In 450 
addition, P-selectin/PSGL-1 interactions are important determinants of cellular 451 
passage across the blood-CSF barrier36. Our screen also identified the 452 
chemokine receptor CXCR3 and the protease SERPINE1 as inducible by IL-453 
15. CXCR3 is highly expressed in CSF leucocytes and its ligand CXCL10 is 454 
up-regulated in the CSF of multiple sclerosis patients41, suggesting that 455 
CXCR3 may be important in CNS cell-entry.  SERPINE1 is a serine protease 456 
inhibitor that inhibits apoptosis42 and plays important roles in cellular invasion 457 
and angiogenesis43. It is associated with poor prognosis in a variety of 458 
cancers44. Interestingly the gene encoding SERPINE1 is a known ERK1/2 459 
target45. 460 
 461 
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IL-15 induces phosphorylation of ERK1/2 and STAT5. Interestingly, both 462 
these signalling pathways are implicated in ALL pathogenesis. Constitutive 463 
activation of the Raf/Ras/MEK/ERK pathway is common in childhood ALL and 464 
acquired Ras mutations are considered to be driver mutations46. STAT5 465 
activation is strongly associated with high-risk ALL subsets such as 466 
Philadelphia positive ALL47 and “Philadelphia-like” ALL48, both of which are 467 
associated with high-risk MRD and relapse. The growth advantage conferred 468 
by IL-15 is completely blocked by inhibition of ERK1/2. In contrast, STAT5 469 
inhibition reduces overall leukaemic cell growth but does not abolish the 470 
growth-promoting effects of IL-15 suggesting it may play a role in other, as yet 471 
unidentified mechanisms, related to disease aggressiveness. The specific role 472 
of the PI3K/Akt pathways and NFκB pathways needs further investigation – 473 
our results show that inhibition of these pathways abrogates IL-15 growth 474 
effects but due to the requirement for these pathways for basal leukaemic cell 475 
growth in culture further analysis will be required to determine whether these 476 
effects are direct or indirect.  477 
 478 
Finally, it is worth noting that IL-15 may also influence the immune response 479 
to ALL. Administration of IL-15 has been suggested as a potential cancer 480 
treatment by boosting anti-tumour immune responses49. Although our studies 481 
did not address the effects of IL-15 on host immune cells, our findings, along 482 
with others18-20, suggest that in ALL the increased malignant cell biological-483 
fitness associated with high IL-15 might out-compete an increased immune 484 
response. Whether IL-15 has similar effects on growth of non-haematological 485 
malignancies is currently unknown, although IL-15 SNPs have also been 486 
linked to colon cancer50.  487 
 488 
Importantly, this paper illustrates how high-throughput unbiased approaches 489 
such as GWAS and microarray data can lead to focused studies investigating 490 
key biological drivers of disease that can be exploited by drug therapy. Our 491 
study provides not only an insight into mechanisms by which IL-15 promotes 492 
leukaemic cell growth and a propensity for LN and CNS involvement but also 493 
identifies potential drug targets. 494 
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 664 
FIGURE LEGENDS 665 
 666 
Figure 1: 667 
IL-15 and IL-15 receptor expression by pre-B ALL cells and correlation 668 
with CNS infiltration. (A) RT-PCR analysis of IL-15 isoform and IL-15 669 
receptor expression by cell lines and primary patient samples. Expected sizes 670 
in brackets; LSP-IL-15 (201bp), SSP-IL-15 (320bp), IL-15Rα (402bp), IL-671 
15/2Rβ (403bp), IL-15/2Rγ (447bp), GAPDH (Housekeeping control) (115bp). 672 
Representative examples are shown; individual results are listed in 673 
supplementary table 1. (B) SYBR green relative quantification of IL-15 mRNA 674 
expression in primary patient samples using SD-1 as the calibrator 675 
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(expression in patient samples reported as fold change relative to the level of 676 
expression in SD-1 cells, arbitrarily set at 1). (C) Histological analysis of 677 
murine brains and spinal cord from xenografts. Top panel left to right: SD-1, 678 
Sup-B15 and REH H&E stained sections showing dark purple leukaemic cells 679 
infiltrating the meninges (thick arrows) (all x10 magnification, black scale bars 680 
represent 100µm). Bottom panel immunohistochemistry for human CD45 681 
confirms the human origin of these infiltrating cells (isotype control shown in 682 
small inset panel) (x40 magnification, black scale bars represent 100µm). 683 
Bottom right panel, section through spinal cord from SD-1 xenograft; stars 684 
mark the sites of leukaemic infiltration in the meningeal covering of the spinal 685 
cord (x20 magnification, black scale bars represent 100µm). (D) Time to hind-686 
limb paralysis of cell line xenografts, 4-8 mice per cell line. (E-H) Taqman 687 
qPCR analysis of IL-15 and all three components of the IL-15 receptor 688 
complex in xenografted cell lines. Three independent cultures were analysed 689 
per cell line, all results are expressed relative to the level in Sup-B15 cells, 690 
arbitrarily set at 1.0. All data are mean ± S.E.M and were analysed by  student 691 
t-tests comparing SD-1 cells to each of the other cell lines . ***p<0.001, 692 
**p<0.01, *p<0.05, n.s = not significant.   693 
 694 
Figure 2 695 
Pre-B ALL primary cells and SD-1 cells show increased growth in the 696 
presence of IL-15. (A) Six different primary pre-B ALL samples were grown in 697 
optimised 3-cytokine mix with or without addition of IL-15 (25ng/ml). Numbers 698 
of viable blast cells were measured at weeks 1, 2 and 3 by flow cytometry. 699 
Each sample is shown individually and then results from all 6 experiments are 700 
pooled (bottom panel, data represent mean ± S.E.M) (B) Fold change in cell 701 
numbers compared to baseline (starting cell count at initiation of the 702 
experiment) was calculated for the two experimental conditions in each of the 703 
6 primary samples. Data were analysed using a Wilcoxon matched-pairs sign 704 
rank test, bars display mean ± S.E.M. (C) Growth of SD-1, Sup-B15, REH and 705 
SEM cells following treatment with 1, 5 or 25 ng/ml IL-15 for up to 96 h. (D) 706 
Growth of SD-1 and SupB-15 cells following treatment with media alone, 6 707 
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g/ml isotype control antibody or 6 g/ml of IL-15R nAb. Viable cells were 708 
determined using trypan blue. Data represent mean ± S.E.M. Data were 709 
analysed using an unpaired student t test. *p<0.05 and are representative of 3 710 
independent experiments carried out per cell line. 711 
 712 
Figure 3: 713 
IL-15 has no effect on apoptosis in SD-1 cells. (A) Intracellular IL-15 714 
protein levels in SD-1 and Sup-B15 cells, measured by flow cytometry with 715 
isotype (shaded) and IL-15 specific Ab (open). Corrected mean fluorescence 716 
intensity (MFI) represents MFI IL-15PE – MFI isotype control. (B) Levels of IL-717 
15Rβand γ in SD-1 and Sup-B15 cells, determined by western blot with -718 
tubulin as a loading control. MOLT-4 cells expressing high levels of IL-15R 719 
were used as a positive control (C) Western blot for BCL-xL and BCL-2 720 
protein expression in SD-1 cells treated with IL-15 (1, 5 and 25 ng/ml) for 72 721 
h. (D) PARP cleavage in SD-1 cells treated with IL-15 (25 ng/ml) for 96 h. The 722 
positive control lane contains SD-1 cells treated with the apoptosis-inducing 723 
agent AA2 (50 M) for 1 h. Histone H3 was used as loading control. (E) 724 
Annexin V-FITC and PI staining of SD-1 cells treated with (right panel) or 725 
without (central panel) 25 ng/ml IL-15 for 96h. The positive control shows cells 726 
exposed to AA2 (50 M) for 1 h (left panel). (F) SD-1 cells (dark bars) and the 727 
dexamethasone sensitive cell line CCRF-CEM (light bars; used as a positive 728 
control) were exposed to vehicle (0.1% EtOH) or dexamethasone (100 nM, 1 729 
M or 10 M) for 48h. Percentage apoptosis (sum of early and late apoptosis) 730 
of these cells was then measured using an Annexin V assay. Data represent 731 
mean ± S.E.M with n=3 for each cell line. (G) SD-1 (dark bars) and CCRF-732 
CEM cells (light bars) were exposed to similar conditions as (C) for 48 h and 733 
viability was assessed using an MTT assay. Data show viability (% of control) 734 
compared to untreated control. (H) MTT assay of SD-1 (dark bars) and CCRF-735 
CEM (light bars) cells exposed to dexamethasone (10µM) ± IL-15Rα 736 
nAb/isotype control for 72 h. In (F) – (H), data represent mean +/- SEM (n=3) 737 
and were analysed using a Kruskal Wallis test with Dunn’s multiple 738 
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comparison test. **p<0.01, ***p<0.001. 739 
Figure 4: 740 
IL-15 promotes growth of SD-1 cells under low serum conditions, which 741 
is independent of apoptosis. (A) SD-1 cells were grown in RPMI media 742 
without addition of FCS, with (dashed line) or without (solid line) 25ng/ml of IL-743 
15. The growth curve from one representative experiment of 3 is shown (B) 744 
SD-1 cells were grown in RPMI supplemented with increasing concentrations 745 
of FCS with (black bars) or without (white bars) 25ng/ml of IL-15. The total 746 
number of viable cells in each group at 72 hours is shown. Data represent 747 
mean ± SEM from 3 independent experiments. Data were analysed by a 748 
Mann-Whitney test. *p<0.05, **p<0.01, ***p<0.001. (C) Percentage increase in 749 
cell counts of IL-15 treated SD-1 (dark bars) and Sup-B15 (light bars) 750 
compared to media control. Data represent mean ± SEM from 3 independent 751 
experiments. SD-1 data is from the same experiments as in (B) above 752 
represented in a different format. (D) PARP cleavage analysis of SD-1 cells 753 
exposed to increasing concentrations of serum ± 25ng/ml IL-15 for 96 h. The 754 
positive control lane represents SD-1 cells exposed to the apoptosis-inducing 755 
agent AA2 (50 M) for 1 h. Histone H3 was used as a loading control. 756 
Figure 5: 757 
IL-15 is not directly chemotactic but induces expression of molecules 758 
associated with leukocyte trafficking. (A) SD-1 cells were placed in the top 759 
section of a bare filter transwell (5 M pore size) and exposed to IL-15 (1, 10, 760 
100, 300 or 1000 ng/ml) in the bottom section of the transwell. Transmigration 761 
was assessed following a 3 h incubation period. Migration index was 762 
calculated by counting the total number of cells transmigrated cells in 763 
response to IL-15 as a proportion of the total number of cells that 764 
transmigrated in response to chemotaxis buffer alone (spontaneous 765 
migration). Data shown are from one experiment performed in triplicate. (B) 766 
SD-1 cells (n=3 independent cultures) were treated with IL-15 (25 ng/ml) for 767 
72 h and levels of mRNA encoding PSGL-1 and CXCR3 measured by qPCR. 768 
Results are expressed as relative quantities with the level in media alone 769 
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arbitrarily set to 1.0. (C) SD-1 cells (n=3 independent cultures) were treated 770 
as in (B) and the surface expression of PSGL-1 and CXCR3 was analysed by 771 
FACS. Corrected mean fluorescence intensity (cMFI) represents MFI specific 772 
antibody – MFI isotype control. (D) Following IL-15 treatment as in (B) above, 773 
expression of 95 genes associated with tumour metastasis was assessed 774 
using a commercially available RT2 PCR profiler array. Data are represented 775 
as a scatter plot (RQ log10) and solid lines represent 2 fold down- or up-776 
regulation. The 7 genes showing >2 fold change with IL-15 treatment are 777 
listed. (E) Validation of hits from (D) by qPCR of SD-1 cells (n=3 independent 778 
cultures) treated with media ± IL-15 (25 ng/ml) for 72 h confirmed modest up-779 
regulation of Serpine1 by IL-15. Data show the number of copies of Serpine 1 780 
per 1000 copies of the housekeeping control gene TBP. All data are mean ± 781 
S.E.M and were analysed by unpaired student t-tests. *p<0.05, **p<0.01, 782 
***p<0.001.  783 
 784 
Figure 6: 785 
STAT5 and ERK1/2 signalling pathways are activated by IL-15 in SD-1 786 
cells. (A) SD-1 cells were treated with IL-15 (25 ng/ml) for 15, 30, 45, 60 or 787 
120 min. Cell lysates were analysed by western blot using antibodies as 788 
indicated. (B) Western blot band density was analysed via ImageJ software 789 
(NIH) and adjusted densitometry values for p-STAT5 calculated by dividing 790 
the relative densities for p-STAT5 by the relative densities for total STAT5. (C) 791 
Adjusted densities values for p-ERK1/2 and (D) p-IBwere calculated in a 792 
manner similar to above, except that relative densities for total ERK1/2 and 793 
IBwere used respectively. 794 
 795 
Figure 7: 796 
IL-15-induced proliferation of SD-1 cells is mediated via the MEK/ERK 797 
signalling pathway. SD-1 cells were treated with (A) 10 M ERK1/2 inhibitor 798 
(dashed lines), (B) 100 M STAT5 inhibitor (dashed lines),  (C) 10 M MEK 799 
inhibitor (dashed lines), (D) 5µM NFκB inhibitor (IKK-2 inhibitor IV) or 20µM 800 
PI3K inhibitor (LY 294002) or matched vehicle controls (0.1% DMSO) (solid 801 
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lines) with (solid symbols) or without (open symbols) additional IL-15 802 
(25ng/ml). Viable cell numbers were determined using trypan blue. Data are 803 
mean ± S.E.M. Unpaired student t-tests were used to compare cell counts at 804 
72 and 96h in drug treated IL-15 vs. no IL-15 groups. *p<0.05, **p<0.01, n.s = 805 
no significant difference. Vehicle treated IL-15 vs. no IL-15 groups showed 806 
significant (p<0.05) increase in cell numbers with IL-15 treatment at 72 and 807 
96h as previously shown (figure 2c). Representative graphs of 3 independent 808 
experiments are shown. 809 
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Supplementary Data 
ALL patient and cell line details 
ID Sex Age 
(Years) 
WCC 
(x10
9
/l) 
Cytogenetics Immunophenotype CNS 
status 
Outcome IL15 
RQ 
IL15 
LSP 
IL15 
SSP 
IL15 
Rα 
IL15 
Rβ 
IL15 
Rγ 
Cell lines 
SD1 F n/k n/k t(9;22) CD34+, CD10neg, CD19+,  
Cyt79a+ 
n/k n/k 1 Y Y Y Y Y 
Sup 
B15 
M 8 n/k t(9;22) CD10+, sIg neg n/k n/k 0.082 Y Y Y Y Y 
REH F 15 n/k t(12;21) CD34neg, CD10+, CD19+,  
Cyt79a+ 
n/k Established at time of 
1
st
 relapse 
0.384 Y Y Y Y Y 
SEM F 5 n/k t(4:11) CD34neg, CD19+,   n/k Established at time of 
1
st
 relapse 
0.337 Y N Y Y Y 
Patients 
G01 M 2 23 11q23 CD34+,  TdTneg, CD10+, 
CD19+, Cyt79a+ 
1 CCR  
(19 months) 
2.09 Y Y Y Y Y 
G02 F 5 29 t(12;21) CD34lo, TdT+,  CD10+, 
CD19+, Cyt79a+ 
1 CCR  
(19 months) 
0.44 Y N Y Y Y 
G06 M 4 52 t(12;21) CD34+,  TdT+, CD10+, CD19+, 
Cyt79a+ 
1 CCR  
(13 months) 
0.44 Y Y Y Y Y 
G07 M 10 3 Normal CD34+,  TdT+, CD10+, CD19+, 
Cyt79a+ 
1 CCR  
(13 months) 
1.93 Y Y Y Y Y 
G08 F 11 35 dic(7;9) CD34+,  TdT+, CD10lo, 
CD19+, Cyt79a+ 
1 CCR  
(13 months) 
0.80 Y N Y Y Y 
G09 F 6 23 Hyperdiploid CD34+,  TdT+, CD10+, CD19+, 
Cyt79a+ 
1 CCR  
(13 months) 
0.21 Y Y Y Y Y 
G11 M 10 14 High 
Hyperdiploid 
CD34+,  TdT+, CD10+, CD19+, 
Cyt79a+ 
TLP+ CCR  
(11 months) 
0.48 Y N Y Y Y 
G16 M 2 90 High 
Hyperdiploid  
CD34+,  TdT+, CD10+, CD19+, 
Cyt79a+ 
1 CCR  
(10 months) 
0.10 Y N Y Y Y 
G17 F 3 50 t(12;21) CD34+,  TdT+, CD10+, CD19+, 
Cyt79a+ 
1 CCR  
(9 months) 
1.34 Y Y Y Y Y 
E2 F 3 34.4 Hyperdiploid CD34+,  TdT+, CD10+, 
Cyt79a+ 
1 CCR 
(21 months) 
0.56 Y N Y Y Y 
Table S1: Patient and cell line details and results of IL-15 and IL-15 receptor RT-PCR and IL-15 qPCR. n.d = not done due to lack 
of material. CCR=continuous complete remission. n/k = not known. CNS-1 (CSF white cell count (WCC) <5/µl, no blasts), CNS-2 
(WCC<5/µl, visible blasts) or CNS-3 (WCC>5/µl), TLP+ = traumatic lumbar puncture with visible blasts. *= death due to 
haemorrhage. 
E3 F 6 9.6 t(12;21) CD34+,  TdT+, CD10+, 
Cyt79a+ 
1 CCR  
(21 months) 
2.56 Y N Y Y Y 
E4 M 3 16.8 Hyperdiploid CD34+,  TdT+, CD10+, CD20+, 
Cyt79a+ 
1 CCR  
(20 months) 
1.86 Y N Y Y Y 
E5 F 2 4.3 t(12;21) CD34lo,  TdT+, CD10+, 
Cyt79a+ 
1 Died during 
induction* (week 3)  
0.56 Y N Y Y Y 
5449 F 2.5 62.2 t(12;21) B-precursor 1 CCR  
(5.3 years) 
0.37 Y N Y N Y 
4630 F 2.9 103.6 t(12;21) B-precursor 1 CCR  
(7.0 years) 
0.20 Y N Y N Y 
5094 F 2.1 84.6 t(12;21) B-precursor 3 CCR 
(6.6 years) 
n.d Y N Y N Y 
4736 F 3.5 113.3 t(12;21) B-precursor 1 CCR 
(6.1 years) 
n.d Y Y Y Y Y 
5705 F 3.4 221 t(12;21) B-precursor 1 CCR  
(4.7 years) 
n.d Y N n.d n.d n.d 
6294 F 1.8 24.5 High 
Hyperdiploid 
B-precursor 1 CCR  
(3.0 years) 
n.d Y N n.d n.d Y 
B200 F 2.9 n/k t(12;21) CD34+, TdT+, CD10+, CD19+, 
Cyt79a+ 
n/k Relapsed 
(20 months) 
n.d n.d n.d n.d n.d n.d 
B247 M 2 n/k t(12;21) CD34+, TdT+, CD10+, CD19+, 
Cyt79a+ 
n/k CCR 
(2.7 years) 
n.d n.d  n.d n.d n.d n.d 
B265 F 5.9 n/k t(12;21) CD34+, TdT+, CD10+, CD19+ n/k CCR 
(10 months) 
n.d n.d n.d n.d n.d n.d 
B197 M 4 n/k t(1:19) CD34neg, TdT+, CD10+, 
CD19+, Cyt79a+ 
n/k CCR 
(4.25 years) 
n.d n.d n.d n.d n.d n.d 
B286 M 4.5 n/k High 
Hyperdiploid 
B-precursor n/k CCR 
(9 months) 
n.d n.d n.d n.d n.d n.d 
B282 F 0.66 n/k Hyperdiploid B-precursor n/k Consolidation therapy 
(3 months) 
n.d n.d n.d n.d n.d n.d 
  
RT-PCR 
Target Sequence Annealing 
temperature 
Product size 
IL-15 5′ AAA CCC CTT GCC ATA GCC AGC TCT T 
3′ CTT CTG TTT TAG GAA GCC CTG CAC T 
55oC 201bp LSP-IL-15 
320bp SSP-IL-15 
IL-15Rα 5′ GCC AGC GCC ACC CTC CAC AGT AA 
3′ GCC AGC GGG GGA GTT TGC CTT GAC  
55oC 402bp 
IL-15Rβ 5′ CAC AGA TGC AAC ATA AGC TGG 
3′ ACT TCA GGA CCT TCT TCA GCC  
52oC 403bp 
IL-15Rγ 5′ AGC CCC AGC CTA CCA ACC TCA CT 
3′ TTA AAG CGG CTC CGA ACA CGA A 
55oC 447bp 
Serpine 1 5′ GGTTCTGCCCAAGTTCTCC 
3′ CGGTCATTCCCAGGTTCTC 
60oC 71bp 
GAPDH* 5′ CAAGGCTGAGAACGGGAA 
3′ GGTGGTGAAGACGCCAGT  
55oC 115bp 
 
Taqman primers/probes   
Gene Assay ID Gene Assay ID 
GAPDH * Hs99999905_m1 CX3CR1 Hs00365842_m1 
IL-15 Hs99999039_m1 CXCR7 Hs00604567_m1 
IL-15Ralpha Hs00542604_m1 CXCR6 Hs00174843_m1 
IL-15/2Rbeta Hs01081697_m1 CXCR5 Hs00173527_m1 
IL-15/2Rgamma Hs00173950_m1 CXCR2 Hs00174304_m1 
TBP* Hs00427620_m1 CXCR1 Hs00174146_m1 
ICAM3 Hs00233674_m1 CCR10 Hs00706455_s1 
ICAM2 Hs00168384_m1 CCR8 Hs00174764_m1 
ICAM1 Hs99999152_m1 CCR6 Hs00171121_m1 
ITGB7 Hs00168469_m1 CCR4 Hs99999919_m1 
ITGB2 Hs00164957_m1 CCR3 Hs00266213_s1 
ITGB1 Hs01127543_m1 CCR1 Hs00174298_m1 
ITGA4 Hs00168433_m1 SELPLG Hs00380945_m1 
ITGAL Hs00158238_m1 CCR2 Hs00174150_m1 
ITGAM Hs00355885_m1 CCR5 Hs00152917_m1 
NCAM1 Hs00941821_m1 CXCR3 Hs00171041_m1 
SELL Hs01046459_m1 CCR7 Hs01013469_m1 
18sRNA* Hs99999901_s1 CXCR4 Hs00237052_m1 
Table S2: Primer/probe details for quantitative PCR. All Taqman probes were 
FAM-MGB labelled and were obtained from Applied Biosystems. *Endogenous 
control genes. 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
Full length Caspase-3 (35 kDa)
Caspase-3 cleaved products (17 
& 19 kDa)
1 2 3 4 5 6 7 8 9
1 = NO FCS 
2 = NO FCS + IL-15
3 = 2.5% FCS 
4 = 2.5% FCS + IL-15
5 = 5% FCS 
6 = 5% FCS + IL-15
7 = 10% FCS 
8 = 10% FCS + IL-15
9 = AA2 (50 mM) 6 h – positive control 
b-Tubulin (55-57 kDa)
Figure S1: Effect of IL-15 on apoptosis and cell division in SD-1 cells grown under low 
serum conditions and in the absence and presence of IL-15. (a) SD-1 cells were exposed 
to differing concentrations of serum (0-10%) ± IL-15 (25 ng/ml) for 96 h. Whole cell lysates 
were created and then analysed for caspase-3 cleavage. The positive control lane represents 
SD-1 cells exposed to apoptosis activator compound 2 (AA2) (50 mM) for 1 hour. β-tubulin is 
shown as a loading control. (b) CellTrace Violet was used to analyse the number of cell 
divisions in IL-15 treated vs. untreated cells under normal and low serum conditions. Results 
are expressed as the percentage reduction in mean fluorescence intensity in IL-15 treated 
versus untreated cells measured after 72 hours incubation *p≤0.05, **p≤0.0.1. (c) As in (a) but 
using AnnexinV as a measure of apoptosis. 
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* The following genes had no detectable transcripts by qPCR: CCR1, CCR2, CCR3, 
CCR5, CXCR1, CXCR2, CXCR5, CXCR6, CX3CR1, NCAM. 
 
Figure S2: Quantitative PCR for selectins, integrins and chemokine receptors in 
SD1 cells grown for 72 hours in media alone or media plus 25ng/ml IL-15. All data are 
shown as mean ± S.E.M and were analysed by a student t-test., *p≤0.05.   
 Figure S3: CXCR3 and PSGL-1 functional assessment. (a) Chemotaxis of REH cells 
to the CXCR3 ligand CXCL10, 5x106 cells were washed and re-suspended in chemotaxis 
buffer (RPMI 1640 with 5 mg/ml BSA) and placed in the upper chamber of a transwell 
assay (5µM transwell  filters, Corning). Chemotaxis buffer +/- 300ng/ml CXCL10 was 
added to the bottom chamber. Following incubation for 3 h at 37oC, 5% CO2, 
transmigrated cells in the bottom well were counted using a haemocytometer with trypan 
blue dead-cell exclusion or by FACS analysis.  Each condition was tested in triplicate 
wells. (b) Immunoassay for CXCL10 (Luminex, Invitrogen) was performed on CSF 
samples taken during induction therapy from one ALL patient with CNS-3 disease and 2 
CNS-1 patients. (c) Immunohistochemical staining for the PSGL-1 receptor P-selectin 
using CD62P Antibody IHC-plus™ LS-B3578 (LifeSpan BioSciences) or isotype control in 
paraffin embedded sections of brain tissue from NSG mice showing meningeal covering 
and vessels within the meninges. A = meningeal arteriole, V = meningeal venule, P= 
Brain parenchyma 
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Figure S4: qPCR validation of possible IL-15 target genes using SYBR green 
absolute quantification.  SD1 cells were treated with 25ng/ml IL-15 or media 
control for 72 hours. mRNA was extracted and cDNA synthesized and SYBR-green 
qPCR was performed using TATA binding protein as the housekeeping gene. The 
data is from 3 independent experiments each conducted in triplicates. Graph 
represents mean and SEM. 
 
 Figure S5: Effect of STAT5 and MEK inhibitors on the transcriptional response to IL-15. 
SD1 cells were treated with STAT5 inhibitor (573108, 10 µM) or MEK inhibitor (U0126, 1 µM) 
with or without IL15 (25ng/ml) in 10% FCS in RPMI for 72 hours. mRNA was extracted, cDNA 
synthesised. Gene expression was compared between media and IL-15 treated cells using 
Taqman gene expression assays for CXCR3 and PSGL1 using GAPDH as housekeeping 
gene. Data were analysed using 2ΔΔCT method on ABI RQ manager v1.2.1. Data is pooled 
from 3 independent experiments. Bars represent mean and SEM. *p<0.05    
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